Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07694544 · ClinicalTrials.gov registry record · Phase 1
Renal Impairment Study for Oral EC5026
A Phase 1 study, sponsored by EicOsis Human Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07694544 is a Phase 1 study that is actively recruiting participants, run by EicOsis Human Health. The registered enrollment target is 18 participants.
The verdict
NCT07694544, a Phase 1 study, is actively recruiting participants, sponsored by EicOsis Human Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are: 1. To determine if the PK of a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD differs from age-matched healthy participants with normal kidney function. 2. To determine if a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD is safe and well tolerated. Researchers will compare a single 8 mg dose of oral across participants with varying degrees of kidney function impairment (either normal kidney function, or stage 3b chronic kidney disease \[CKD\], or state 4/5 CKD). Participants will be asked to take a single oral dose of EC5026 and will be monitored with PK laboratory assessments and safety assessments (including physical exams, vital signs, electrocardiograms, and others).
Interventions
- DRUG EC5026 oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07694544
The ClinicalTrials.gov registry entry for NCT07694544 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EicOsis Human Health, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EC5026 oral tablet is the first listed.
NCT07694544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07694544 about?
NCT07694544 is a clinical study titled "Renal Impairment Study for Oral EC5026". The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are: 1. To determine if the PK of a single 8 mg dose of EC5026, administered orally, in adult participants with varying ...
What is the current status of trial NCT07694544?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-07-01. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT07694544?
The interventions under investigation include: EC5026 oral tablet (DRUG).
Who is sponsoring clinical trial NCT07694544?
This trial is sponsored by EicOsis Human Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.